promising, information regarding outcome at 30 days is limited. We evaluated outcomes after TAVI with S3 THV with particular emphasis on the updated Valve Academic Research Consortium (VARC-2) criteria.
METHODS 261 consecutive patients undergoing transfemoral TAVI with S3 THV at our center were enrolled and outcome according to the VARC-2 criteria was analyzed at 30 days.
RESULTS Mean age was 81AE6 years and median logistic EuroScore was 12% [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . Follow-up at 30 days was available for 260 patients. VARC-2 defined device success was achieved in 251 (96%) of patients; 5 (2%) cases developed moderate paravalvular leakage. At 30 days, one patient (0.4%) died due to a noncardiac cause and 8 (3%) patients suffered from a disabling (n¼4) or non-disabling stroke (n¼4). Life-threatening bleeding and major vascular complications occurred in 12 (5%) and 7 (3%) of the cases, respectively. From discharge to 30 days, 5 (2%) patients were hospitalized due to valve-related symptoms or worsening of heart failure. The VARC-2 composite early safety endpoint at 30 days, all-cause mortality, disabling and non-disabling stroke, life-threatening bleeding, acute kidney injury, coronary artery obstruction requiring intervention, major vascular complication, or valve-related dysfunction requiring repeat procedure was observed in 23 (9%) patients. Permanent pacemaker implantation rate at 30 days was 16% (38 of the 235 patients without pacemaker at baseline) and with 30-days follow-up. Myocardial infarction, coronary obstruction requiring intervention, valve-related dysfunction and endocarditis were not observed.
Clinical outcome in-hospital and at 30 days CONCLUSIONS We found very good 30-day results using a novel balloon expandable S3 THV with a low rate of severe clinical events according to the VARC-2 composite early safety endpoint. The novel balloon expandable S3 THV is associated with a high procedural success rate and favorable early safety profile considering the VARC-2 composite endpoint. The need for pacemaker implantations appears to be more frequent than that seen with its predecessor. 3 Wing Tech Inc., Irvine, CA BACKGROUND Our objective was to estimate the impact of availability of transcatheter heart valve replacement (TAVR) therapy on overall heart valve replacement volumes and aortic valve disease mortality over a longer-term horizon, using the German healthcare system as a reference case, which was among the first systems adopting TAVR therapy in routine care.
METHODS We collected therapy-and age-specific procedure volumes from records of the German Federal Statistics Office for TAVR and surgical aortic valve replacement (SAVR) procedures for years [2009] [2010] [2011] [2012] [2013] . Relevant ICD-10 diagnosis-based information about discharges and hospital-based mortality were obtained for the same period. We computed therapy-specific and total procedure volumes and growth stratified by 5-year age increments and in total. Discharge and mortality data for aortic valve disease hospitalizations was assessed to obtain an estimate of changes in per-case mortality.
RESULTS Overall procedure volumes grew from 26,466 in 2009 to 33,235 in 2013 (þ26%) . This growth was driven by TAVR (3,411 to 10,814; þ217%), while SAVR volumes remained stable (23,055 to 22,421; -3%). In patients 75 years or older, an overall procedure growth of 51% was observed (12,168 to 18,318), with volumes in older patient segments growing more heavily (þ62% in >80-year olds; þ101% in >85-year olds). Across all elderly age groups, SAVR volumes decreased (-20% in >80 year olds; -37% in >85 year olds), while they grew in selected younger patients groups (highest growth þ30% in age group 60-64 yrs. BACKGROUND To overcome limitations of transapical and transseptal access to deliver large caliber transcatheter implants to the mitral valve, we hypothesized that the left atrium could be accessed through the posterior chest wall by displacing the lung with CO2 under imaging guidance.
METHODS We tested fully percutaneous transthoracic left atrial access in 12 animals (10 pigs and 2 sheep) and 3 human cadavers under real-time magnetic resonance imaging (n¼10) or x-ray fluoroscopy plus C-arm computed tomographic (n¼2) guidance. We also simulated transthoracic trajectories to the left atrium on human contrastenhanced cardiac computed tomographic angiograms.
RESULTS Animals were survived for median 7.5 days (Q1-Q3, 7-8.5 days). The pleural space was insufflated with CO2 to displace the lung, an 18-26F sheath was delivered to the left atrium, and the left atrial port was closed using an off-the-shelf nitinol cardiac occluder (Amplatz Atrial Septal Occluder) successfully in 12/12 animals. There was no procedural mortality and no important change in hemodynamics (heart rate, mean arterial pressure and expired CO2). Median bleeding into the pericardium and pleura were 55mL (40-73mL) and 10mL (10-75mL) respectively, which were immediately auto-transfused.1 hemodynamically insignificant pericardial effusion was observed at follow-up. We also successfully accessed and closed the left atrium in 3 human cadavers under real-time magnetic resonance (n¼1) or X-ray fluoroscopic guidance (n¼2 (Table) deemed unsuitable for treatment with any CE marked device by Heart Team Evaluation underwent TMVI using a Tendyne system (a tri-leaflet porcine pericardial valve in a tethered self-expanding nitinol frame, with an apical tether fixed to an epicardial pad to stabilize the device). The device is fully repositionable and retrievable even after complete deployment. Device size was chosen based on multidetector computed tomography (MDCT) tomography to define mitral annular dimensions, geometry and guide surgical access. Annular dimensions were confirmed by intra-operative 3-dimensional transoesophageal echocardiography. The device was implanted under TOE-guidance using general anesthesia via a transapical approach through a small left mini-thoracotomy using a 34Fr sheath which was advanced over the wire into the left atrium. The device was advanced into the sheath, extruded, positioned into the correct anatomical position by rotating the device, and fully deployed. The apical pad was inserted into position over the tether. The tension on the tether was then adjusted to optimize the position of the device. The apical pad facilitated LV apical closure.
RESULTS TMVI procedures were performed between October 2014 and January 2015. All patients had no paravalvular MR, no transvalvular MR, and no transmitral gradient immediately after TMVI (Table) . One patient (who had previous mitral annuloplasty) developed significant LVOTO (95mmHg) associated with systolic anterior motion of the mitral valve. Following LVOT stenting, LVOT gradient decreased to 47mmHg. All 4 patients were discharged to their own home, independent of activities of daily living. At 6-months, all were alive, living independently at home, with no further heart failure hospital admissions. All showed improvement in functional capacity and 6-minute walk test. All valves were stable, with reduction in tricuspid regurgitation and pulmonary pressures. Two patients had evidence of mild paravalvular regurgitation and were asymptomatic but with biochemical evidence of hemolysis. 
